4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany. These data include an overview on the clinical development activities of the pan-HDAC inhibitor resminostat, currently in Phase II trials in hepatocellular cancer and Hodgkin's lymphoma, a profile of its second, selective-HDAC inhibitor 4SC-202 and an introduction to 4SC-207, an anti-mitotic cell cycle blocker.

'Our presence at EORTC underlines our commitment to developing oncology candidates that will offer an improved and targeted standard of care for cancer patients,' said Bernd Hentsch, Chief Development Officer, 4SC. 'We have focused our resources over the last three years in order to establish a pipeline of clinical and preclinical compounds targeting molecular pathways for various tumour types and hold the promise to provide more tailored treatment for patients.'

Poster Presentations by 4SC:

Resminostat (4SC-201):

Abstract: #540, Poster Board: #076 Title: Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM, Poster session on 'Genetics and epigenetics' Poster Presenter: Rüdiger Jankowsky, Anna Mais, Stefan W. Henning, Bernhard Hauns, Bernd Hentsch

Abstract: #542 Poster board: #078 Title: Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi) Session date and time: 19 Nov 2010, 8:00 AM - 9:30 AM, Poster session on 'Genetics and epigenetics' Poster Presenter: Bernhard Hauns, Anna Mais, Rüdiger Jankowsky, Bernd Hentsch, Wilhelm Haverkamp

4SC-202:

Abstract: #178 Poster board: #135 Title: Preclinical Characterization of 4SC-202, a novel isotype specific HDAC inhibitor Session date and time: 17 Nov 2010, 12:00 - 14:30 AM, Poster session on 'Molecular-targeted therapies-preclinical' Poster Presenter: Stefan W. Henning, Robert Doblhofer, Hella Kohlhof, Rüdiger Jankowsky, Thomas Maier, Thomas Beckers, Matthias Schmidt and Bernd Hentsch

4SC-207:

Abstract: #501 Poster Board: #037 Title: 4SC-207, a novel and highly potent anti-mitotic agent, active also on PgP expressing tumor cells resistant to other chemotherapeutic drugs, induces complete tumor stasis in in vivo tumor models Session date and time: 19 Nov 2010, 8:00 - 9:30 AM, Poster session on 'Cell-cycle-interactive agents' Poster Presenter: Aldo Ammendola, Rolf Krauss, Robert Doblhofer, Stefan Strobl, Svetlana Hamm, Matthias Schmidt, Petra Gimmnich, Klaus Pekari, Astrid Zimmermann, Bernd Hentsch

Source: 4SC